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Abstract
Background and Aim: Treatment with sorafenib causes diverse side effects, which
limits adherence. This work assesses whether Home Care, a psychosocial nursing
intervention, prolongs the duration of treatment in patients with advanced hepatocellu-
lar carcinoma (HCC) and if it influences health-related quality of life (HRQL).
Methods and Results: This is a cohort study using data from patients receiving
sorafenib in the prospective Bern HCC Cohort at the University Hospital. Duration of
treatment, overall survival, and HRQL using the Functional Assessment of Cancer
Therapy-Hepatobiliary questionnaire were compared in the two groups. A total of
173 patients were eligible for the analysis. Among them, 141 were in the Home Care
program, and 32 were not. Patients with Home Care had a significantly longer dura-
tion of treatment (265 days vs 152 days, P = 0.003) and a better functional well-being
(17.7 vs 12.5, P = 0.015).
Conclusion: Psychosocial interventions such as Home Care are a valid method in
improving adherence to sorafenib and can therefore be recommended.
Introduction
Hepatocellular carcinoma. Hepatocellular carcinoma
(HCC) is among the most common types of cancer and the sec-
ond most common cause of cancer-related death worldwide.1
The most common risk factors are hepatitis B virus (HBV) infec-
tion, hepatitis C virus (HCV) infection, unhealthy alcohol use,
non-alcoholic steatohepatitis (NASH), and metabolic diseases
such as hemochromatosis.2,3
The management of HCC is complex, but there is a large
number of potentially useful therapies.4 Well-established treat-
ments include surgical resection, liver transplantation, or local
ablation, which are potentially curative, and palliative therapies
such as chemoembolization and sorafenib, which aim to improve
survival. Treatment allocation should be based on the Barcelona
Clinic Liver Cancer (BCLC) staging system.5
The tyrosine–multikinase inhibitor drug sorafenib was
approved as the first systemic treatment of advanced stages of
HCC in 2008.6 The benefit of sorafenib over placebo has been
shown in two randomized, double-blind, multicenter phase III tri-
als.7,8 Since then, sorafenib is recommended for patients with
preserved liver function (Child-Pugh-A class) and advanced
BCLC stage C.9
Although there are many benefits of the treatment with
sorafenib, the drug has shown different adverse effects that need
to be taken into account. Most of the side effects are considered
manageable to a certain degree. Those include diarrhea, fatigue,
nausea and vomiting, hand–foot skin reaction, anorexia, and
hypertension. Notwithstanding the lack of apparent danger, these
tolerable toxicities may influence the quality of life.10
Interestingly, the occurrence of certain side effects corre-
lates with response to treatment. The disease control rate and sur-
vival in patients with skin toxicity were better compared to those
with no skin reactions.11,12 Similar observations have been made
for diarrhea and hypertension.9,13,14
Health-related quality of life. Health related quality of
life (HRQL) is increasingly becoming an outcome of interest in
disease management. Patients with chronic liver disease or HCC
report a worse overall HRQL compared to the general popula-
tion.15 Several studies in the past have identified HRQL as a
valuable prognostic factor in patients with hepatobiliary can-
cer.16-20 Recent research has shown that the evaluation of HRQL
also increases the accuracy of survival prediction in HCC when
added to the Eastern Cooperative Oncology Group Performance
Status, which is used in the BCLC staging system.21
Generic and disease-specific measures to assess HRQL
have been developed over the past few decades.22,23 The most
widely used tool is the Functional Assessment of Cancer
Therapy-General (FACT-G) questionnaire.24 This 27-item score
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consists of the following four subscores, where patients rate the
accurateness of different statements from 0 to 4: physical well-
being (e.g. I am in pain, I lack energy), social well-being (e.g. I
am supported by my family, my family has accepted my dis-
ease), emotional well-being (e.g. I feel sad, I feel hopeless), and
functional well-being (FWB; e.g. I have accepted my disease, I
sleep well). The score was later supplemented by the 18-item
Hepatobiliary Cancer Subscale (HCS) to form the more specific
45-item instrument for hepatobiliary cancers known as the Func-
tional Assessment of Cancer Therapy-Hepatobiliary question-
naire (FACT-Hep).25 The HCS consists of additional questions
regarding specific issues such as jaundice, itching, fever, and gas-
trointestinal symptoms. Two further studies support the validity
of the FACT-Hep in assessing disease-related symptoms and
clinically meaningful disease progression.26,27
A limited number of studies has looked into the HRQL
assessed by the FACT-Hep in patients with HCC. Overall,
patients with HCC show worse HRQL but better social and fam-
ily well-being.15 In addition, the FACT-Hep has been used to
evaluate the effect of several treatments.28-31
The benefit of prescribed medication is often decreased
due to lack of adherence of patients due to subjective or objec-
tive side effects. Similarly, nonadherence is also spread among
sorafenib patients, which is of concern due to increasing use and
cost of such oral oncology medications.32 Interventions such as
intensive support, information, and counseling are widely used to
enhance the adherence of people who are prescribed self-
administered medications. Methods currently used are complex
and mildly effective.33 Furthermore, Steel et al.34 have shown a
clinically significant rise in HRQL due to an individually tailored
psychosocial intervention in patients with HCC.
Strategies such as patient education, an open dialog
between patients and the health-care team, and reporting of
adverse events have been evaluated for sorafenib. Such interven-
tions minimize the necessity of dose reduction or discontinuation
of sorafenib.35
Similarly, MediService, a mail-order pharmacy of Switzer-
land, offers so-called Home Care support for their patients treated
with sorafenib (Nexavar, Bayer, Austria). Home Care consists of
a personal visit after prescription and registration, one phone call
per month, the possibility of inbound calls, and further individual
approaches. The goal is the management of adverse events in
order to attain better adherence and thus maximize treatment
duration for as long as the indication is given.
The MediService Home Care Team covers Switzerland
and is multilingual. All team members possess an appropriate
level of professional nursing education and long-term experience.
Home Care is free of charge. It is offered to all patients with a
sorafenib prescription.
The aim of this article is to investigate the effect of Home
Care support on the treatment duration of sorafenib and overall
survival. In addition, the study estimates the HRQL using the
FACT-Hep in patients with and without Home Care before and
under therapy with sorafenib.
Methods
Design. This study is a retrospective analysis of prospectively
acquired data. The data were obtained from the Bern HCC
cohort, which is a prospective cohort study that was started on
the 1st of August 2010 at the University hospital of Bern. All
patients aged at least 18 years with a diagnosis of HCC in the
last 12 months are enrolled after signing an informed consent
form. A valid diagnosis of HCC must be established by either
noninvasive criteria (typical radiological hallmarks) or pathology
according to the European Association for the Study of the Liver
clinical practice guidelines.5 A total of 136 different variables
(i.e. demographic, clinical, laboratory, radiological, treatment,
and HRQL data) are evaluated at inclusion and reevaluated at
follow-up every 3 months. The end of data collection for this
analysis was the 31st of December 2019. Included were all the
patients from the cohort who received sorafenib at inclusion or
during the observational time. Using the information from
MediService, the patients were sorted into two groups: The first
group included patients who were in the Home Care program,
and the second group included patients not in the Home Care
program. The groups were then compared, and mean sorafenib
treatment duration, overall survival, and the FACT-Hep scores
evaluated.
Methods. For this analysis, we used the demographic data
obtained at inclusion. For the other baseline parameters such as
tumor stage and laboratory parameters, the data corresponding to
the time when sorafenib was prescribed were used (either at
inclusion or at the next follow-up visit).
Treatment duration was defined as the time from the date
of beginning of sorafenib therapy (day of first order of
sorafenib at MediService) to the time of death, switching to
another therapy, or stopping for another reason such as intolera-
ble side effects or progression of disease. Overall survival was
defined as the time from the beginning of sorafenib therapy to
the time of death, last follow-up evaluation, or the date of data
censoring.
To determine HRQL, the FACT-Hep questionnaire was
used.25 It consisted of physical (PWB), social/family (SWB),
emotional (EWB), and FWB, and the disease-specific HCS sub-
scores. PWB, SWB, EWB and FWB were added to form the
FACT-G score. Adding the HCS to the FACT-G formed the
FACT-Hep total score. Furthermore, the Trial Outcome Index
(TOI), a summary index of physical/functional outcomes often
used in clinical trials testing physical health interventions such as
pharmaceutical treatments, was calculated by combining PWB,
FWB, and HCS scores. All 45 items used a 5-point scale ranging
from “not at all” (0) to “very much” (4). The questionnaires were
scored according to the Functional Assessment of Chronic Illness
Therapy manual.36
HRQL was compared first at inclusion provided a ques-
tionnaire was filled out before the start of therapy with sorafenib.
Second, the follow-up FACT-Hep after the start of therapy with
sorafenib was compared.
A second analysis excluding patients with BCLC stage D
and/or Child-Pugh C class was conducted to eliminate a possible
large effect size of this small sample of patients with advanced
stage of HCC, which is not typically suitable for sorafenib
treatment.
Analysis. For comparison of the two groups, means and stan-
dard deviations were calculated. The chi square test was used to
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calculate P-values for categorical variables. For continuous vari-
ables, the t-test was applied. Curves for cumulative survival rates
were calculated using the Kaplan–Meier method and compared
by the log-rank test. A P-value of <0.05 was considered statisti-
cally significant.
The information was extracted into an encoded Excel file
after collection. Missing values were specifically retrieved from
the hospital database. All calculations were conducted using
SPSS version 26. All data were prospectively collected and retro-
spectively analyzed.
Ethics. The local ethics committee (Kantonale Ethikkom-
mission Bern, Bern, Switzerland) approved the collection of
patient information and the study protocol (2018-00347), which
was consistent with the principles of the current version of the
Declaration of Helsinki.
Table 1 Baseline characteristics
Home Care No Home Care
P value
n = 141 n = 32
n % n %
Age† 66 63 0.082
Gender 0.167
Male 120 85.1 24 75
Female 21 14.9 8 25
BMI† 27.5 27.5 0.985
Comorbidity
Alcohol‡ 21 14.9 5 15.6 0.862
Smoking 39 27.7 6 18.8 0.341
Treatment§
Resection 28 19.9 6 18.8 0.887
TACE 29 20.6 4 12.5 0.294
TAE 17 12.1 3 9.3 0.668
RFA 5 3.5 1 3.1 0.885
MWA 9 6.4 3 9.3 0.548
SIRT 14 9.9 1 3.1 0.217
External radiotherapy 7 5 0 0.0 0.198
Etiology¶
Alcohol 63 44.7 8 25 0.041
HBV 23 16.3 6 18.8 0.739
HCV 42 29.8 10 31.3 0.871
NASH 50 35.5 9 28.1 0.429
Haemochromatosis 10 7.1 1 3.1 0.406
BCLC 0.709
0 0 0.0 0 0.0
A 2 1.4 1 3.1
B 46 32.6 12 37.5
C 90 63.8 19 59.4
D 3 2.1 0 0.0
Child-Pugh Grade 0.294
A 75 60.3 13 56.3
B 48 34.8 12 37.5
C 3 2.1 2 6.3
MELD† 10 11 0.408
Creatinine (μmol/L)† 83.2 79.1 0.545
Bilirubin (μmol/L)† 26.6 41 0.102
INR† 1.14 1.21 0.238
AFP (kU/L)† 4930.7 4741.8 0.957
†Mean value.
‡Defined as ongoing consumption of >30 g/day.
§Some patients have undergone multiple treatments before sorafenib.
¶Patients can have multiple etiologies.
P values marked in bold denote statistical significance at the p < 0.05 level.
AFP, alpha 1 fetoprotein; BCLC, Barcelona Clinic Liver Cancer; BMI, body mass index; HBV, hepatitis B virus; HCV, hepatitis C Virus; INR, Interna-
tional normalized ratio; MELD, Model For End-Stage Liver Disease; MWA, microwave ablation; NASH, non-alcoholic steatohepatitis;; RFA, radio-
frequency ablation; SIRT, selective internal radiation therapy; TACE, transarterial chemoembolization.
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Results
Baseline characteristics of the entire group. Adding
the data of MediService to the Bern HCC Cohort resulted in the
identification of a total of 197 eligible patients treated with
sorafenib. After the exclusion of 24 patients (insufficient data:
16 cases, liver transplantation: 8 cases), 173 patients remained
for the evaluation. The Home Care group consisted of
141 patients overall, whereas the No Home Care group included
32 patients.
The demographic and tumor characteristics, as well as the
treatments before sorafenib, of these two groups are summarized in
Table 1. This population was composed of 83% males, with a mean
age of 66 years. Most patients (n = 89, 51.4%) had previously
received another treatment for HCC. Resection was the most com-
mon treatment (19.7%) followed by transarterial chemoembolization
(19.1%) and transarterial embolization (11.6%). Sorafenib was use
as the first line therapy in 48.6% patients The most frequent etiol-
ogy was alcohol-induced liver disease (41.0%), followed by NASH
(34.1%), HCV (30.1%), HBV (16.8%), and hemochromatosis
(6.4%). On sorafenib initiation, 88 (50.9%), 60 (34.7%), and
5 (2.9%) were classified as Child-Pugh classes A, B, and C, respec-
tively. According to the BCLC staging system, 3 (1.7%),
58 (33.5%), 109 (63%), and 3 (1.7%) patients were assigned to
stage A, B, C, or D.5
Both groups were comparable for most of the parameters,
except liver disease etiology: 44.7% had alcohol-induced liver
disease in the Home Care group versus 25% in the No Home
Care group.
A separate analysis excluding the six patients with BCLC
stage D and/or Child-Pugh class C showed comparable results
with the same difference in etiology.
Duration of treatment and overall survival. The
main analysis of this study was the comparison of the mean dura-
tion of treatment. Table 2 displays the mean duration of treat-
ment for the two groups with a significantly higher value in the
Home Care group (265 compared to 152 days, P = 0.003).
In addition, the overall survival of the two groups was
compared. Figure 1 shows the Kaplan–Meier analysis for overall
survival. In accordance with the prolonged treatment duration in
the Home Care group, overall survival is longer in this cohort
(391 vs 288 days). However, this result is not significant
according to the log-rank test.
Comparing the groups without the six patients with
advanced stages showed similar results.
Health-related quality of life. Table 3 shows the FACT-
Hep questionnaire with the total scores and subscores at inclu-
sion and after start of therapy. In both groups, a large number
of scores could not be calculated because of missing data due
to different reasons such as incomplete questionnaires or
completely missing questionnaires due to lacking language
knowledge or different or unknown reasons. In the Home Care
group, the number of missing values ranged from 51 to 53 at
inclusion and from 86 to 89 at follow-up. In the No Home Care
group, there were 17 missing values for each score at inclusion
and follow-up.
At inclusion, the means were 100.5 for the TOI score,
83.3 for the FACT-G, and 142.8 for the FACT-Hep with no sig-
nificant difference between the two groups and likewise for the
subscores. At follow-up, the mean TOI, FACT-G, and FACT-
Hep values were lower (87.9, 77.3, and 130.0, respectively). The
analysis of the two groups at follow-up showed a TOI score of
89.0 in the Home Care group compared to 84.0 in the No Home
Care group, a FACT-G of 78.3 in the Home Care group and 73.8
for the No Home Care group, and FACT-Hep of 131.4 in the
Home Care group and 124.9 for the No Home Care group. These
were not significantly different (P = 0.311, 0.249, and 0.304).
However, the FWB was significantly lower in the No Home Care
group (12.5 vs 17.7 with P = 0.015).
In the same way as for baseline characteristics, treatment
duration, and overall survival, the results for HRQL were inter-
changeable when excluding patients with BCLC stage D and
Child-Pugh class C.
Table 2 Mean duration of treatment
Home Care No Home Care
n = 141 n = 32 P value
Duration of treatment (day) 265 152 0.003
P values marked in bold denote statistical significance at the p < 0.05 level.
Figure 1 Kaplan–Meier analysis for overall survival. Compares
patients with Home Care to patients without Home Care. Log-rank test:
P = 0.300. Whole cohort: , Home Care; , no Home Care; ,
Home Care censored; , no Home Care censored.
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Discussion
The aim of this study was to evaluate the efficacy of Home Care
support in patients treated with sorafenib. The Home Care and
No Home Care groups were compared in terms of treatment
duration, overall survival, and HRQL. The results showed a sig-
nificantly longer treatment duration and a better survival rate in
the Home care group but without statistical significance. Con-
cerning the HRQL, only the subscore FWB was significantly
lower in the No Home Care group.
The baseline characteristics (i.e. gender, median age)
of the studied population were in line with previously publi-
shed data.2,3,37 Most patients were classified as BCLC stage
C when therapy with sorafenib was started, which is not sur-
prising because the BCLC guidelines suggest systemic treat-
ment with sorafenib at that stage.9 Strikingly, the etiology of
alcoholic steatohepatitis was found more frequently in the
Home Care group. One possible explanation is that this risk
factor might predispose to a certain insecurity, leading to a
more help-seeking behavior and thus participation in the
Home Care program. Previous studies have shown that psy-
chosocial treatment is recommended in patients with alco-
holic liver disease as it is successful in educating and
motivating patients.38
Despite the higher prevalence of the alcoholic etiology,
known to be predisposed to noncompliance, we found that the
Home care group had a longer duration of therapy compared to
the No Home Care group.39
Home Care intervention offers close accompaniment and
frequent contact with the patients, which allows a better under-
standing of their general physical conditions and the disease
itself. During the initial visits, the patients are informed about
possible medication side events, drug reactions, and the impor-
tance of adherence to treatment. In addition, patients received
follow-up phone calls every month, and further individual
approaches were taken. All these measurements allow a deeper
understanding of the therapy goals and the side effects and trans-
late into a longer duration of therapy. Although there is a paucity
of research evidence on the effectiveness of patient educational
interventions, such methods may enhance adherence and, conse-
quently, maximize health outcomes and quality of life.40
In addition to treatment efficacy, the patients’ quality of
life has to be taken into consideration. In line with previous
reports, we observed that the mean values of the whole cohort
before and under therapy shows a decline in every section except
for SWB for both groups. This might be explained as being a
result of support by family and friends, from which patients with
HCC benefit.15,22
Another interesting finding was that the No Home Care
group had a lower FWB score under therapy compared to the
Home Care group. During Home Care visits and phone calls,
some of the issues included in this score are addressed directly.
For instance, the ability to sleep, disease acceptance, and the
ability to enjoy free time are thus improved.
Side effect management is a major part of Home Care,
which may improve several items of different subscores of the
Table 3 Health-related quality of life (HRQL)
Home Care No Home Care
P value
n = 141 n = 32
n† Missing values‡ Score§ n† Missing values‡ Score§
Baseline HRQL
PWB 89 52 21.8 15 17 23.1 0.341
SWB 89 52 24.3 15 17 23.4 0.572
EWB 89 52 18.1 15 17 18.7 0.585
FWB 90 51 18.9 15 17 19.3 0.795
HCS 89 52 59.9 15 17 58.3 0.510
TOI total 88 53 100.5 15 17 100.7 0.961
FACT-G total 89 52 83.1 15 17 84.5 0.738
FACT-Hep total 88 53 142.8 15 17 142.8 0.992
Follow-up HRQL
PWB 53 88 17.9 15 17 20.3 0.111
SWB 54 87 24.5 15 17 23.9 0.693
EWB 55 86 17.7 15 17 17.0 0.530
FWB 55 86 17.7 15 17 12.5 0.015
HCS 54 87 53.4 15 17 51.1 0.422
Trial Outcome Index total 53 88 89.0 15 17 84.0 0.311
FACT-G total 53 88 78.3 15 17 73.8 0.249
FACT-Hep total 52 89 131.4 15 17 124.9 0.304
†Number of patients with complete scores.
‡Number of patients with missing scores.
§Mean value.
P values marked in bold denote statistical significance at the p < 0.05 level.
EWB, emotional well-being; FACT-G, Functional Assessment of Cancer Therapy-General; FACT-Hep, Functional Assessment of Cancer Therapy-
Hepatobiliary; FWB, functional well-being; HCS, Hepatobiliary Cancer Subscale; PWB, physical well-being; SWB, social well-being.
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FACT-Hep (e.g. pain, diarrhea). Apart from FWB, the subscores
were nonsignificantly higher in the Home Care group at follow-
up, except for physical well-being. Although the impact in num-
bers seems modest, we believe that even a small improvement of
HRQL is clinically significant and, for each individual, relevant.
Unfortunately, there is no additional data available regarding side
effect management and patient satisfaction.
The group with Home Care also shows longer overall sur-
vival, without reaching statistical significance. This supports the
thesis that sorafenib is an effective therapy and that treatment
adherence is crucial for a beneficial outcome. The difference of
overall survival was around 100 days, which is in accordance
with the modest net benefit of sorafenib shown in previous
studies.41
Study limitations. Despite the prospectively acquired data
and although the study represents the management of HCC in a
tertiary university center in Switzerland, there are certain limita-
tions. In the current study, a relatively small number of patients,
particularly in the group without Home Care, was analyzed.
Moreover, for HRQL, there were only limited data available.
This might strongly limit the power of the analysis. Furthermore,
the study was neither randomized nor blinded, which could
potentially lead to selection bias. It must, however, be said that,
although randomization would be desirable, blinding seems
inherently difficult in this context. Nevertheless, this study offers
insight into the benefits of the Supplementary health-care act of
Home Care.
As for our clinic, we will continue to recommend Home
Care for patients treated with sorafenib. A complex and severe
disease such as HCC demands versatile and intense care. There-
fore, the patients usually benefit from closer attendance and
praise the program. Home Care does, of course, not replace any
visit at the hospital but is an advantageous addition. The uptake
in other centers is desirable, although the organization and train-
ing of staff may be limiting. Fortunately, MediService has started
to implement Home Care support in other centers, as well as for
some other drugs.
Conclusion
In conclusion, this preliminary study shows that Home Care pro-
longs treatment duration with sorafenib and improves FWB. The
effect on overall survival remains elusive. Based on our findings,
we believe that Home Care intervention should be recommended
for patients treated with sorafenib and possibly other systemic
therapy.
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